Submitted:
19 December 2024
Posted:
20 December 2024
You are already at the latest version
Abstract

Keywords:
1. Introduction
2. Materials and Methods
2.1. The Gene Expression Profiling Studies by Xavier et al. and Oguz et al.
2.2. Retrieval of the Expression Data
2.3. The Demographic and Clinical Data of the Study Population and the Definition of the Clinical Subsets of Patients with Behçet Syndrome
2.4. Excluded Samples/Cases
2.5. Statistical Analysis of the Demographic Characteristics
2.6. Pre-Processing of the Microarray Data
2.7. Bioinformatics Analyses of the Gene Expression Data
3. Results
3.1. Demographics of the Study Population
3.2. Pre-Processing Results of the Microarray Data
3.3. Class Comparison Analyses
3.4. Venn Diagram Analyses
3.5. Cluster Analyses
3.6. Functional Enrichment Analyses
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Yazici, Y.; Hatemi, G.; Bodaghi, B.; et al. Behçet syndrome. Nat Rev Dis Primers 2021, 7, 67. [Google Scholar] [CrossRef] [PubMed]
- Behçet, H.; Matteson, E.L. On relapsing, aphthous ulcers of the mouth, eye and genitalia caused by a virus. 1937. Clin Exp Rheumatol 2010, 28, S2-5. http://www.ncbi.nlm.nih.gov/pubmed/20868561.
- Jennette, J.C.; Falk, R.J.; Bacon, P.A.; et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013, 65, 1–11. [Google Scholar] [CrossRef] [PubMed]
- Gül, A. Behçet Disease. In Textbook of Autoinflammation; Hashkes, P.J., Laxer, R.M., Simon, A., Eds.; Springer International Publishing: Cham, Switzerland, 2019; pp. 647–665. [Google Scholar] [CrossRef]
- Mat, M.C.; Bang, D.; Lee, E.S.; Kutlubay, Z. The Mucocutaneous Manifestations and Pathergy Reaction in Behçet Syndrome. In Behçet Syndrome; Yazici, Y., Hatemi, G., Seyahi, E., Yazici, H., Eds.; Springer International Publishing: Cham, Switzerland, 2020; pp. 37–50. [Google Scholar] [CrossRef]
- Keino, H.; Okada, A.A. Behcet’s disease: global epidemiology of an Old Silk Road disease. British Journal of Ophthalmology 2007, 91, 1573–1574. [Google Scholar] [CrossRef] [PubMed]
- Direskeneli, H.; Saruhan-Direskeneli, G. Disease Mechanisms. In Behçet Syndrome; Yazici, Y., Hatemi, G., Seyahi, E., Yazici, H., Eds.; Springer International Publishing: Cham, Switzerland, 2020; pp. 209–222. [Google Scholar] [CrossRef]
- Yurdakul, S. Epidemiology of Behçet Syndrome and Regional Differences in Disease Expression. In Behçet Syndrome; Yazici, Y., Hatemi, G., Seyahi, E., Yazici, H., Eds.; Springer International Publishing: Cham, Switzerland, 2020; pp. 21–35. [Google Scholar] [CrossRef]
- Leccese, P.; Yazici, Y.; Olivieri, I. Behcet’s syndrome in nonendemic regions. Curr Opin Rheumatol 2017, 29, 12–16. [Google Scholar] [CrossRef] [PubMed]
- Leonardo, N.M.; McNeil, J. Behcet’s Disease: Is There Geographical Variation? A Review Far from the Silk Road. Int J Rheumatol 2015, 2015, 1–7. [Google Scholar] [CrossRef] [PubMed]
- Oğuz, A.K.; Yılmaz, S.T.; Oygür, Ç.Ş.; et al. Behçet’s: A Disease or a Syndrome? Answer from an Expression Profiling Study. PLoS One 2016, 11, e0149052. [Google Scholar] [CrossRef] [PubMed]
- Oğuz, A.K.; Oygür, Ç.Ş.; Taşır, S.; Özdağ, H.; Akar, M.N. Behçet syndrome: The disturbed balance between anti- (CLEC12A, CLC) and proinflammatory (IFI27) gene expressions. Immun Inflamm Dis 2023, 11. [Google Scholar] [CrossRef] [PubMed]
- Xavier, J.M.; Krug, T.; Davatchi, F.; et al. Gene expression profiling and association studies implicate the neuregulin signaling pathway in Behçet’s disease susceptibility. J Mol Med 2013, 91, 1013–1023. [Google Scholar] [CrossRef]
- Brazma, A.; Hingamp, P.; Quackenbush, J.; et al. Minimum information about a microarray experiment (MIAME)—toward standards for microarray data. Nat Genet 2001, 29, 365–371. [Google Scholar] [CrossRef] [PubMed]
- Gene Expression Omnibus. https://www.ncbi.nlm.nih.gov/geo/.
- BRB-ArrayTools. https://brb.nci.nih.gov/BRB-ArrayTools/.
- Irizarry, R.A. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4, 249–264. [Google Scholar] [CrossRef]
- Venny 2.1.0. https://bioinfogp.cnb.csic.es/tools/venny/index.html.
- Cluster 3.0. http://bonsai.hgc.jp/~mdehoon/software/cluster/.
- Java TreeView. https://jtreeview.sourceforge.net/.
- WebGestalt. https://www.webgestalt.org/.
- González-Amaro, R.; Cortés, J.R.; Sánchez-Madrid, F.; Martín, P. Is CD69 an effective brake to control inflammatory diseases? Trends Mol Med 2013, 19, 625–632. [Google Scholar] [CrossRef] [PubMed]
- Radulovic, K.; Niess, J.H. CD69 is the crucial regulator of intestinal inflammation: a new target molecule for IBD treatment? J Immunol Res 2015, 2015, 497056. [Google Scholar] [CrossRef]
- Gorabi, A.M.; Hajighasemi, S.; Kiaie, N.; et al. The pivotal role of CD69 in autoimmunity. J Autoimmun 2020, 111, 102453. [Google Scholar] [CrossRef] [PubMed]
- Patterson, R.M.; Germolec, D.R. Gene expression alterations in immune system pathways following exposure to immunosuppressive chemicals. Ann N Y Acad Sci 2006, 1076, 718–727. [Google Scholar] [CrossRef]
- Suomela, S.; Cao, L.; Bowcock, A.; Saarialho-Kere, U. Interferon alpha-inducible protein 27 (IFI27) is upregulated in psoriatic skin and certain epithelial cancers. J Invest Dermatol 2004, 122, 717–721. [Google Scholar] [CrossRef]
- Gao, J.; Zhu, X.; Wu, M.; Jiang, L.; Wang, F.; He, S. IFI27 may predict and evaluate the severity of respiratory syncytial virus infection in preterm infants. Hereditas 2021, 158, 3. [Google Scholar] [CrossRef] [PubMed]
- Rao, M.S.; Van Vleet, T.R.; Ciurlionis, R.; et al. Comparison of RNA-Seq and Microarray Gene Expression Platforms for the Toxicogenomic Evaluation of Liver From Short-Term Rat Toxicity Studies. Front Genet 2018, 9, 636. [Google Scholar] [CrossRef]






| Clinical Phenotype | Defining Clinical Characteristics |
|---|---|
| Mucocutaneous BS | Only oral ulcers with genital ulcers and/or skin lesions and/or pathergy test positivity (i.e., isolated mucocutaneous findings) are present. |
| Ocular BS | In addition to mucocutaneous findings, there is only ocular BS involvement, which may present with different ocular lesions. |
| Vascular BS | In addition to mucocutaneous findings, there is only vascular BS involvement without ocular involvement, which may present with different vascular lesions. |
| Other BS | In addition to mucocutaneous findings, there is ocular involvement and/or vascular involvement and/or musculoskeletal involvement and/or gastrointestinal system involvement and/or nervous system involvement. |
| Portuguese | Turkish | p | ||
|---|---|---|---|---|
| Behçet1 | Age2 | 32/20-57 | 34/18-58 | .939 |
| Gender3 | 7/7 | 12/10 | .790 | |
| Control | Age2 | 32/21-62 | 36/19-57 | .715 |
| Gender3 | 7/7 | 10/5 | .362 | |
| Mucocutaneous | Age2 | 29/20-55 | 44/25-57 | .315 |
| Gender3 | 2/5 | 1/7 | .438 | |
| Ocular | Age2 | 39/28-57 | 26/18-58 | 1.000 |
| Gender3 | 3/1 | 2/3 | .294 | |
| Vascular | Age2 | 46/30-50 | 33/27-56 | 1.000 |
| Gender3 | 2/1 | 9/- | .070 | |
| Classes Compared | Number of Differentially Expressed Genes | |||||
| Portuguese | Turkish | |||||
| Total | Increased1 | Decreased2 | Total | Increased1 | Decreased2 | |
| p≤0.05, FC≥1.5 | ||||||
| B vs. C | 29 | 15 | 14 | 450 | 85 | 365 |
| M vs. C | 101 | 79 | 22 | 92 | 41 | 51 |
| O vs. C | 1035 | 376 | 659 | 186 | 58 | 128 |
| V vs. C | 1407 | 313 | 1094 | 3603 | 508 | 3095 |
| p≤0.05, FC≥2.0 | ||||||
| B vs. C | 4 | 3 | 1 | 17 | 6 | 11 |
| M vs. C | 6 | 3 | 3 | 22 | 10 | 12 |
| O vs. C | 178 | 59 | 119 | 13 | 7 | 6 |
| V vs. C | 299 | 60 | 239 | 549 | 81 | 468 |
| Classes Compared | Number of Differentially Expressed Genes | |||||
| p≤0.05, FC≥1.5 | p≤0.05, FC≥2.0 | |||||
| Total | Increased1 | Decreased2 | Total | Increased1 | Decreased2 | |
| PC vs. TC | 12479 | 7726 | 4753 | 6549 | 3898 | 2651 |
| PB vs. TB | 13654 | 8756 | 4898 | 8024 | 5415 | 2609 |
| PMB vs. TMB | 12882 | 8136 | 4746 | 7601 | 4940 | 2661 |
| POB vs. TOB | 12435 | 7840 | 4595 | 7466 | 4814 | 2652 |
| PVB vs. TVB | 12539 | 8047 | 4492 | 8642 | 5827 | 2815 |
| Portuguese | Turkish | ||||||
| Gene Symbol | FC | p | Gene Symbol | FC | p | ||
| B vs. C | |||||||
| 1 | LGALS2 | 1.992 | 0.002764 | 1 | IFI27 | 3.433 | 0.001199 |
| 2 | HBQ1 | 1.647 | 0.020998 | 2 | ARG1 | 2.408 | 0.005611 |
| 3 | DUSP6 | 1.617 | 0.008132 | 3 | CA1 | 2.366 | 0.003222 |
| 4 | DHRS9 | 1.562 | 0.015752 | 4 | DEFA4 | 2.169 | 0.013169 |
| 5 | BCAT1 | 1.554 | 0.009325 | 5 | FKBP5 | 2.080 | 0.000919 |
| 6 | SCARNA17 | -1.573 | 0.023432 | 6 | IGHM | -2.223 | 0.006240 |
| 7 | SRSF3 | -1.610 | 0.028504 | 7 | CLC | -2.467 | 0.000130 |
| 8 | TCL1A | -1.764 | 0.020299 | 8 | LRRN3 | -2.473 | 0.004112 |
| 9 | CCL4 | -1.851 | 0.037743 | 9 | CLEC12A | -2.544 | 1.88e-05 |
| 10 | S100B | -1.912 | 0.010533 | 10 | MS4A1 | -2.573 | 0.002132 |
| M vs. C | |||||||
| 1 | PMAIP1 | 2.094 | 0.017740 | 1 | IFI27 | 3.180 | 0.014886 |
| 2 | HBEGF | 1.978 | 0.045537 | 2 | RSAD2 | 2.586 | 0.046990 |
| 3 | CTSS | 1.957 | 0.028778 | 3 | TMEM158 | 2.437 | 0.006344 |
| 4 | LGALS2 | 1.954 | 0.015461 | 4 | FRMD3 | 1.957 | 0.001215 |
| 5 | RP2 | 1.885 | 0.028528 | 5 | HEMGN | 1.939 | 0.029605 |
| 6 | KHDC4 | -1.618 | 0.022498 | 6 | RPL31 | -1.767 | 0.007869 |
| 7 | YPEL3 | -1.624 | 0.019027 | 7 | TBX1 | -1.770 | 0.002394 |
| 8 | ZBTB20 | -1.689 | 0.027927 | 8 | FOLR1 | -1.849 | 0.000802 |
| 9 | CEACAM8 | -2.110 | 0.030067 | 9 | LRRN3 | -1.919 | 0.020264 |
| 10 | LTF | -2.403 | 0.026766 | 10 | CLEC12A | -2.917 | 0.000339 |
| O vs. C | |||||||
| 1 | LTF | 6.248 | 0.000890 | 1 | FKBP5 | 2.541 | 9.44e-05 |
| 2 | CEACAM8 | 4.601 | 0.002517 | 2 | IFI27 | 2.530 | 6.90e-05 |
| 3 | MMP8 | 4.282 | 0.000217 | 3 | CA1 | 2.396 | 0.037106 |
| 4 | OLFM4 | 4.191 | 0.000123 | 4 | HEMGN | 2.391 | 0.006561 |
| 5 | CA1 | 3.813 | 0.010158 | 5 | GYPA | 2.147 | 0.021081 |
| 6 | RHOH | -3.299 | 0.000195 | 6 | KLRC3 | -1.979 | 0.011210 |
| 7 | G0S2 | -3.576 | 0.015248 | 7 | CDKN1C | -2.019 | 0.000490 |
| 8 | RGS1 | -4.346 | 0.019787 | 8 | HTATSF1P2 | -2.110 | 0.042364 |
| 9 | TMEM107 | -5.634 | 0.002141 | 9 | CLC | -2.484 | 0.004392 |
| 10 | CXCL8 | -7.431 | 0.028743 | 10 | CLEC12A | -2.550 | 0.007083 |
| V vs. C | |||||||
| 1 | HBD | 3.515 | 0.036049 | 1 | ARG1 | 5.825 | 1.20e-06 |
| 2 | AMFR | 3.409 | 0.019229 | 2 | DEFA4 | 4.453 | 0.000350 |
| 3 | HBM | 3.357 | 0.020985 | 3 | IFI27 | 4.353 | 0.000137 |
| 4 | SLC25A37 | 3.008 | 0.016352 | 4 | ANKRD22 | 3.402 | 0.000538 |
| 5 | AHSP | 2.972 | 0.045883 | 5 | CA1 | 3.364 | 0.000554 |
| 6 | SERPINB2 | -3.869 | 0.026684 | 6 | LRRN3 | -4.004 | 8.90e-06 |
| 7 | CD69 | -4.088 | 0.001281 | 7 | FCER1A | -4.234 | 0.000431 |
| 8 | AREG | -5.157 | 0.038336 | 8 | HLA-DQA1 | -4.528 | 0.005208 |
| 9 | RGS1 | -5.895 | 0.014062 | 9 | IGHM | -4.750 | 3.59e-05 |
| 10 | NR4A2 | -6.351 | 0.012487 | 10 | MS4A1 | -5.483 | 1.56e-05 |
| Increased2 | Decreased3 | ||||||
| Gene Symbol | FC | p | Gene Symbol | FC | p | ||
| PB vs. TB | |||||||
| 1 | EGR1 | 60.465 | <1e-07 | 1 | KRT23 | -26.933 | <1e-07 |
| 2 | ANP32E | 58.879 | <1e-07 | 2 | CXCR2 | -27.348 | <1e-07 |
| 3 | PFDN4 | 27.579 | <1e-07 | 3 | MMP9 | -28.789 | <1e-07 |
| 4 | CD69 | 24.972 | <1e-07 | 4 | CMTM2 | -28.891 | <1e-07 |
| 5 | EIF1 | 23.771 | <1e-07 | 5 | CREB5 | -29.943 | <1e-07 |
| 6 | TOB1 | 22.885 | <1e-07 | 6 | KCNJ2 | -30.468 | <1e-07 |
| 7 | RSL24D1 | 20.719 | <1e-07 | 7 | TNFAIP6 | -32.131 | <1e-07 |
| 8 | CXCL8 | 20.430 | <1e-07 | 8 | TNFRSF10C | -32.371 | <1e-07 |
| 9 | PGGT1B | 17.339 | <1e-07 | 9 | CHI3L1 | -37.464 | <1e-07 |
| 10 | MTPAP | 17.304 | <1e-07 | 10 | CYP4F3 | -68.138 | <1e-07 |
| PMB vs. TMB | |||||||
| 1 | EGR1 | 94.318 | <1e-07 | 1 | KCNJ15 | -27.853 | <1e-07 |
| 2 | ANP32E | 62.871 | <1e-07 | 2 | CXCR2 | -28.159 | <1e-07 |
| 3 | RGS1 | 42.910 | <1e-07 | 3 | S100P | -28.366 | <1e-07 |
| 4 | CXCL8 | 38.483 | 0.000013 | 4 | HBM | -28.711 | <1e-07 |
| 5 | CD69 | 36.208 | <1e-07 | 5 | ANXA3 | -28.808 | <1e-07 |
| 6 | PFDN4 | 34.907 | <1e-07 | 6 | KCNJ2 | -30.677 | <1e-07 |
| 7 | EIF1 | 33.547 | <1e-07 | 7 | CREB5 | -34.032 | <1e-07 |
| 8 | TOB1 | 30.600 | <1e-07 | 8 | TNFRSF10C | -35.714 | <1e-07 |
| 9 | DUSP1 | 27.391 | <1e-07 | 9 | CHI3L1 | -49.331 | <1e-07 |
| 10 | SRSF3 | 21.989 | <1e-07 | 10 | CYP4F3 | -74.579 | <1e-07 |
| POB vs. TOB | |||||||
| 1 | ANP32E | 46.044 | <1e-07 | 1 | KCNJ15 | -19.891 | <1e-07 |
| 2 | PFDN4 | 37.971 | <1e-07 | 2 | CMTM2 | -20.443 | <1e-07 |
| 3 | ENO1 | 22.530 | <1e-07 | 3 | PTPRC | -22.346 | <1e-07 |
| 4 | RSL24D1 | 21.910 | <1e-07 | 4 | CXCR2 | -23.248 | <1e-07 |
| 5 | EIF1 | 20.350 | <1e-07 | 5 | TNFRSF10C | -23.901 | <1e-07 |
| 6 | VCAN | 17.577 | <1e-07 | 6 | KRT23 | -27.567 | <1e-07 |
| 7 | CD69 | 17.484 | <1e-07 | 7 | KCNJ2 | -32.120 | <1e-07 |
| 8 | CCR2 | 17.234 | <1e-07 | 8 | TNFAIP6 | -32.919 | 0.000001 |
| 9 | EAF2 | 16.839 | <1e-07 | 9 | WASF2 | -36.497 | <1e-07 |
| 10 | CD74 | 15.582 | <1e-07 | 10 | CYP4F3 | -37.242 | <1e-07 |
| PVB vs. TVB | |||||||
| 1 | EGR1 | 145.449 | <1e-07 | 1 | IL1R2 | -36.898 | 4.00e-07 |
| 2 | ANP32E | 63.300 | <1e-07 | 2 | MGAM | -37.428 | <1e-07 |
| 3 | TOB1 | 26.834 | <1e-07 | 3 | KCNJ15 | -39.927 | <1e-07 |
| 4 | CCR2 | 25.893 | <1e-07 | 4 | CMTM2 | -43.716 | <1e-07 |
| 5 | SET | 23.423 | <1e-07 | 5 | PI3 | -43.869 | <1e-07 |
| 6 | PGGT1B | 22.069 | <1e-07 | 6 | CHI3L1 | -49.435 | 1.00e-07 |
| 7 | MTPAP | 21.498 | <1e-07 | 7 | TNFAIP6 | -49.585 | <1e-07 |
| 8 | JAK1 | 20.178 | <1e-07 | 8 | ANXA3 | -57.418 | <1e-07 |
| 9 | CXCL8 | 19.765 | <1e-07 | 9 | MMP9 | -58.385 | <1e-07 |
| 10 | RASSF5 | 19.421 | <1e-07 | 10 | CYP4F3 | -93.282 | <1e-07 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).